
price close busi januari
develop manufactur market devic
instrument orthoped specialti
biomed devic servic
abund new product cycl support execut
maintain buy pt
bottom line maintain buy rate follow strong finish
cap anoth year market share gain report strong organ revenu
growth in-line preliminari result announc earli januari driven
broad strength across portfolio includ knee mako instrument neurotech
adjust ep in-lin manag guidanc higher end
guidanc rang cg/consensu
us result reinforc thesi continu deliv msd
organ revenu growth take market share across board start
benefit meaning halo effect mako placement someth expect
continue/acceler move forward note underli new product cycl
medsurg ortho/recon support fundament momentum across
market someth feel lost major investor speak
whose focu appear sole mako sum think new product cycl upsid
bia estim view conserv like maintain solid
revenu detail report organ growth support us sale
growth sale growth xfx orthoped grew
xfx strong perform us knee ou knee xfx
us trauma/extrem medsurg continu solid growth driven
strength instrument endoscopi
us respect neurotech spine also strong post growth driven
demand neurotech product off-set soft global spine busi
guidanc provid organ revenu guidanc y/i
someth view conserv given strong finish organ
full year momentum across us ortho
medsurg neurotech heel new product launch mako adopt
adjust ep expect rang inclus
modest headwind recent pass us tax reform well impact
entl acquisit expect close
mako place mako system global y/i inclus
system place us compani first mako placement japan
manag highlight case sinc launch includ
procedur perform nice q/q unsurprisingli
mako util continu impress momentum util growth
y/i q/q continu place system competit
account believ reinforc thesi competit share gain across
entir product portfolio point manag highlight total knee
sale grew faster faster account mako tka system
compar without lastli note place mako
exist account demonstr earli natur opportun
potenti continu momentum beyond
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
factset compani report canaccord genuiti estim
guidanc chang estim provid full-year guidanc
organ revenu growth adjust ep rang
adjust ep expect rang
earn guidanc inclus modest headwind recent pass us tax
reform expect result tax rate
accordingli made follow chang estim
chang estim
adjust revenu estim
maintain pro-forma ep estim
adjust revenu estim
maintain pro-forma ep
adjust revenu estim
pro-forma ep estim
adjust revenu estim
pro-forma ep estim
adjust revenu estim
pro forma ep estim
adjust revenu estim
pro forma ep estim
buy unchang target price januari
biomed devic servic
performanceactualcg estbeat/missconsensusbeat/missnet good gross special oper ex chg pro-forma oper net ep ex one-tim chg result categoryactualcg net sale
figur chang estim
follow strong result accordingli increas revenu ep
estim sum rais price target
pro-forma ep estim valuat base price-to-earnings multipl
pro-forma ep estim
figur matrix discount rate impli share price target
stryker
one world lead medic technolog compani
broadly-bas rang product orthoped signific presenc
medic specialti compani product includ implant use joint
replac trauma spinal surgeri surgic equip surgic
navig system endoscop commun system patient handl
emerg medic equip medic devic product use varieti
buy unchang target price januari
biomed devic servic
oldnew oldnew oldnew net good gross special oper ex chg forma oper net ep ex one-tim chg pe multipl price metric use price-to-earnings valuat analysisbroad large-cap medic devic price-to-earnings multipl forma figur stryker incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price januari
biomed devic servic
stryker corpor quarterli incom statementcanaccord genuiti kyle except per share good technolog special oper ex chg oper ex chg erest incom incom incom ex one-tim chg incom ex one-tim ep ex one-tim chg ep ex acq relat gross oper ex chg oper ex chg ex net charg net ex one-tim growth oper net incom charg ep charg ep ex acq growth net incom charg ep charg ep ex acq
buy unchang target price januari
biomed devic servic
stryker corpor revenu mixcanaccord genuiti kyle mix us y/i y/i xfx/x q/q q/q mixdomest stryker
